Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405075 · ClinicalTrials.gov registry record
Arizona Alzheimer's Disease Research Center (ADRC)
A clinical trial of Alzheimer Disease, sponsored by Banner Health.
- Recruiting
- Registry status
- 550
- Enrollment target
- 5
- Study locations
NCT05405075: Recruiting study of Alzheimer Disease, sponsored by Banner Health.
NCT05405075 is a study of Alzheimer Disease that is actively recruiting participants, run by Banner Health. The registered enrollment target is 550 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05405075, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Banner Health.
- RECRUITING
- Registry status
- 550 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigational treatments, and the study of normal cognitive aging.
Conditions Studied
Study Locations (5)
Arizona
- Banner Alzheimer's Institute - Phoenix
- Barrow Neurological Institute - Phoenix
- Mayo Clinic - Scottsdale
- Banner Sun Health Research Institute - Sun City
- Banner Alzheimer's Institute - Tucson - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-06-30 |
What NCT05405075 shows while recruiting
NCT05405075 is an observational study that tracks outcomes without assigning an intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05405075 lists 5 locations in 1 state (Arizona).
Frequently Asked Questions
What is clinical trial NCT05405075 about?
NCT05405075 is a clinical study titled "Arizona Alzheimer's Disease Research Center (ADRC)". The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain...
What is the current status of trial NCT05405075?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2021-10-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05405075 study?
This clinical trial studies the following conditions: Alzheimer Disease.
Who is sponsoring clinical trial NCT05405075?
This trial is sponsored by Banner Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05405075 being conducted?
This trial has 5 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05405075's enrollment target sits among peer trials
550 49th of 306 higher than 258 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI